Lumateperone: First Approval

@article{Blair2020LumateperoneFA,
  title={Lumateperone: First Approval},
  author={Hannah A. Blair},
  journal={Drugs},
  year={2020},
  volume={80},
  pages={417-423}
}
Lumateperone (Caplyta ® ) is a novel, orally available agent developed by Intra-Cellular Therapies (under a license from Bristol-Myers Squibb) for the treatment of schizophrenia and other neuropsychiatric and neurological disorders. Lumateperone is a first-in-class selective and simultaneous modulator of serotonin, dopamine and glutamate. In December 2019, lumateperone received its first global approval in the USA for the treatment of schizophrenia in adults. The drug is also under clinical… Expand
12 Citations
Evidence On The New Drug Lumateperone (Iti-007) For Psychiatric And Neurological Disorders.
TLDR
Lumateperone represents a new potential option for other psychiatric and neurological diseases, such as behavioural symptoms of dementia or Alzheimer's Disease, sleep disturbances, bipolar depression, and potential future role of this particular compound in personalized treatments. Expand
The role of lumateperone in the treatment of schizophrenia
TLDR
A critical evaluation of the limited information about lumateperone for schizophrenia, its use approved by the US Food and Drug Administration and its consideration for patients with treatment-resistant schizophrenia is presented. Expand
Lumateperone: New Drug or Same Old Drug With a New Dress?
  • B. Limandri
  • Medicine
  • Journal of psychosocial nursing and mental health services
  • 2020
TLDR
The current article reviews the putative effects of this novel mechanism of action on symptoms of schizophrenia as discussed in Phase II and III trials. Expand
Experimental Serotonergic Agents for the Treatment of Schizophrenia
TLDR
Although some serotonergic drugs seem promising for improving the treatment of schizophrenia, further studies regarding the pathophysiological mechanisms of schizophrenia and novel compounds as well as high-quality trials are necessary in order to improve schizophrenia outcomes. Expand
Atypical Antipsychotic Lumateperone Effects on the Adrenal Gland With Possible Beneficial Effect of Quercetin Co-administration
TLDR
Quercetin had a prophylactic effect against lumateperone depressive-like effect on animal behavior and its possible adrenal damage, and coadministration of quercet in and lumatesperone showed improvement of the previously deteriorated parameters. Expand
Fluorine-containing drugs approved by the FDA in 2019
TLDR
Eleven new fluorine-containing FDA-approved drugs have been profiled and details of their discovery and preparation are discussed, including four examples of aromatic fluorine, three aromatic CF3 group, three aliphatic CF3 and one compound with aromaticCF3O group. Expand
Up-to-date expert opinion on the safety of recently developed antipsychotics
TLDR
Overall, newer antipsychotic medications display a good safety profile, with a well-demonstrated lower metabolic liability compared to second-generation antipsychotics, and appear to specifically target negative symptomatology and improving cognitive domains. Expand
Tailor-made amino acid-derived pharmaceuticals approved by the FDA in 2019.
TLDR
This review article profiles 13 new tailor-made AA-derived pharmaceuticals introduced to the market in 2019, and discusses the development form drug-candidates, total synthesis, with emphasis on the core-AA, therapeutic area, and the mode of biological activity. Expand
Agitation and Dementia: Prevention and Treatment Strategies in Acute and Chronic Conditions
TLDR
The present point of view aims at providing an extensive guide to facilitate the identification, prevention, and management of acute and chronic agitation in dementia patients. Expand
Paul Greengard: A persistent desire to comprehend the brain, and also to fix it.
TLDR
How Paul very early on moved away from biophysics to avoid working on nuclear weapons and instead started his career in the pharmacological spheres of a large pharmaceutical company is discovered. Expand
...
1
2
...

References

SHOWING 1-10 OF 32 REFERENCES
Lumateperone (ITI-007) in the Treatment of Bipolar Depression: Results from a Randomized Clinical Trial.
TLDR
The results suggest that lumateperone 42 mg may be a promising new treatment for bipolar depression associated with bipolar I or bipolar II disorder. Expand
F46. LUMATEPERONE (ITI-007): FAVORABLE SAFETY PROFILE IN AN OPEN LABEL SAFETY SWITCHING STUDY FROM STANDARD-OF-CARE ANTIPSYCHOTIC THERAPY IN PATIENTS WITH SCHIZOPHRENIA
TLDR
The lack of metabolic, motor and cardiovascular safety issues presents a safety profile differentiated from standard-of-care antipsychotic therapy, and patients with stable symptoms on other antipsychotics may further improve when switched to lumateperone, with no dose titration needed. Expand
Efficacy and Safety of Lumateperone for Treatment of Schizophrenia: A Randomized Clinical Trial.
TLDR
Lumateperone demonstrated efficacy for improving the symptoms of schizophrenia and had a favorable safety profile as well as well tolerated doses without clinically significant treatment-emergent motor adverse effects or changes in cardiometabolic or endocrine factors vs placebo. Expand
30 Lumateperone (ITI-007) for the Treatment of Schizophrenia: Overview of Placebo-Controlled Clinical Trials and an Open-label Safety Switching Study
TLDR
Lumateperone improved symptoms of schizophrenia with the same trajectory and same magnitude of improvement from baseline to endpoint on the PANSS total score, and was well-tolerated with a favorable safety profile in all studies. Expand
Dopamine D2 receptor occupancy of lumateperone (ITI-007): a Positron Emission Tomography Study in patients with schizophrenia
TLDR
D2RO at plasma steady state of 60 mg ITI-007, a dose that previously demonstrated antipsychotic efficacy in a controlled trial, was determined and likely contributes to the favorable safety and tolerability profile of lumateperone with reduced risk for movement disorders and hyperprolactinemia. Expand
Functional profile of a novel modulator of serotonin, dopamine, and glutamate neurotransmission
TLDR
The combination of in vitro and in vivo activities of this compound support its development for the treatment of schizophrenia and other psychiatric and neurologic disorders. Expand
ITI-007 for the Treatment of Schizophrenia: A 4-Week Randomized, Double-Blind, Controlled Trial
TLDR
Primary analyses indicated that ITI-007 improved negative and depression symptoms and might have expanded therapeutic efficacy in comparison with current antipsychotic drugs in this trial. Expand
ITI-007 demonstrates brain occupancy at serotonin 5-HT2A and dopamine D2 receptors and serotonin transporters using positron emission tomography in healthy volunteers
TLDR
Evidence is provided for a central mechanism of action via dopaminergic and serotonergic pathways for ITI-007 in living human brain and valuable information to aid dose selection for future clinical trials is provided. Expand
Additional results from a 12-month open-label safety study of lumateperone (ITI-007) in patients with stable symptoms of schizophrenia [abstract no. W203 plus poster
  • Annual Meeting of the American College of Neuropsychopharmacology
  • 2019
ITI-007/ITI-722: a new approach for the treatment of sleep maintenance insomnia and sleep disorders associated with psychiatric and neurological diseases [abstract
  • Sleep. 2009;32(Suppl S):A284–5
  • 2009
...
1
2
3
4
...